1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

ESMO 23: Madrid Meeting Hails Padcev/Keytruda Combo As New Bladder Cancer Standard Of Care

 
• By Kevin Grogan

The combination of Astellas and Seagen's antibody-drug conjugate Padcev and Merck & Co's checkpoint inhibitor  Keytruda has shown improvements in survival not previously achieved in a broad population of patients with advanced urothelial carcinoma.  

ESMO 23 queue
• Source: ESMO

Delegates at the European Society for Medical Oncology meeting in Madrid were delighted to see two Phase III trials for the first-line treatment of urothelial carcinoma (UC) read out with positive overall survival results but the one that had the audience on their feet hailing a new standard of care was the combination of Seagen Inc.  and Astellas Pharma, Inc.'s Padcev and Merck & Co., Inc.'s Keytruda.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

In Brief: Boehringer Ingelheim, Tessellate Bio Link For Precision Therapies For ALT Tumors

 
• By Sushmita Panda

In its first pharma collaboration, Tessellate Bio has inked a deal potentially worth more than €500m with Boehringer Ingelheim for therapies for ALT tumors.

Data From China Bolster Summit/Akeso’s Case For Ivonescimab

 
• By Alaric DeArment

Results from the Phase III HARMONi-6 trial showed the PD-1/VEGF bispecific antibody beating out BeiGene’s Tevimbra in NSCLC.

Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC

 
• By Alaric DeArment

The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

More from Therapy Areas

Genentech To Try Repertoire’s Immune Synapse Technology In Autoimmune Disease

 
• By Joseph Haas

Deal snapshot: The Flagship portfolio firm will use its Decode platform to seek novel targets for an unspecified autoimmune disease, with Genentech holding license rights.

Sebela’s Tegoprazan Poised For GERD Market

 
• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 
• By Sushmita Panda

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.